SCHEMBL4466734

SCHEMBL4466734

CSc1ncnc2sc(-c3c(-c4cccc(I)c4)ncn3C)cc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 6/20 0.58
FLT1 P17948 2/20 0.58
KDR P35968 2/20 0.58
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
KDM4E B2RXH2 6/20 0.40
HPGD P15428 3/20 0.40
RAB9A P51151 3/20 0.40
MAPT P10636 3/20 0.40
NPC1 O15118 2/20 0.40
LMNA P02545 2/20 0.40
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
HTT P42858 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ALDH1A1 P00352 9/20 0.39
POLB P06746 3/20 0.39
NPSR1 Q6W5P4 3/20 0.39
NOD2 Q9HC29 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4799951 0.89 TEK (0.57) TEKFLT1KDRKMT2AMEN1
SCHEMBL4796150 0.89 TEK (0.72) TEKFLT1KDRKMT2AMEN1
SCHEMBL4797446 0.89 TEK (0.57) TEKFLT1KDRKMT2AMEN1
SCHEMBL4481073 0.86 TEK (0.78) TEKFLT1KDRKMT2AMEN1
SCHEMBL4799294 0.83 TEK (0.57) TEKFLT1KDRKMT2AMEN1
SCHEMBL4801246 0.83 TEK (0.57) TEKFLT1KDRKMT2AMEN1
SCHEMBL4477405 0.83 TEK (0.55) TEKFLT1KDRKMT2AMEN1
SCHEMBL4800323 0.81 TEK (0.55) TEKFLT1KDRKMT2AMEN1
SCHEMBL4801478 0.81 TEK (0.45) TEKFLT1KDRKMT2AMEN1
SCHEMBL4797363 0.76 TEK (0.53) TEKFLT1KDRKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476677-B2 Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of Tie2 ASTRAZENECA AB (SE) 2009-01-13 US disclosed
US-7427616-B2 Condensed pyridines and pyrimidines with tie2 (TEK) activity ASTRAZENECA AB (SE) 2008-09-23 US disclosed
EP-1716155-B1 SUBSTITUTED THIENO- AND THIAZOLO[2,3-D]PYRIMIDINES AND [2,3-C]PYRIDINES AS INHIBITORS OF TIE2 ASTRAZENECA AB (SE) 2008-02-27 EP disclosed
US-20070135455-A1 Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 ASTRA ZENECA AB (SE) 2007-06-14 US disclosed
EP-1537112-B1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2006-04-19 EP disclosed
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity ASTRAZENECA AB (SE) 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135455-A1 Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 TIE1, TEK, TEKT1 TEK 2/4885FLT1 6/4885KDR 4/4885
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity TIE1, TEK, KDR TEK 2/4885FLT1 6/4885KDR 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.